Myokardia Inc (MYOK): Anastasios Gianakakos , CEO of Myokardia Inc purchased 2,279 shares on Apr 29, 2016. The Insider buying transaction was reported by the company on May 6, 2016 to the Securities and Exchange Commission. The shares were purchased at $8.50 per share for a total value of $19,371.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Nov 5, 2015, Jonathan C Fox (Chief Medical Officer) purchased 3,000 shares at $10.00 per share price.On Nov 5, 2015, Anastasios Gianakakos (CEO) purchased 1,350 shares at $10.00 per share price.Also, On Nov 5, 2015, Mark L Perry (director) purchased 5,000 shares at $10.00 per share price.On Nov 5, 2015, Sanofi (10% owner) purchased 900,000 shares at $10.00 per share price.
MyoKardia Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). In addition the Company is evaluating MYK-461 and initiated a Phase I clinical program for the treatment of HCM.